$AQST SEC Filings

Acquired 62,229 shares (Other Transaction)

150023820.2 AMENDED AND RESTATED BYLAWS OF AQUESTIVE THERAPEUTICS, INC. (As of October 1516[●], 20242026) ARTICLE I STOCKHOLDERS Section 1. The annual meeting of the stockholders of Aquestive Therapeutics, Inc. (the “Corporation”) for th...

Sold 25,000 shares ($106K)

Holds 0 shares of Common Stock

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 • FDA accepted the resubmission as complete and classified it as a Class 2 response • Prescription Drug User Fee Act (PDU...

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film • Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal...

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotech...

Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Pri...

H.C. Wainwright 28th Annual Global Investment Conference September 14, 2026

Sold 25,000 shares ($120K)

Received 8,750 shares by exercise or conversion ($23.2K) · Sold 8,750 shares ($45.7K)

Received 2,293 shares by exercise ($2.2K)

Received 91,743 shares by exercise ($88.1K)

Received 4,587 shares by exercise ($4.4K)

Sold 25,000 shares ($107K)

Gave up 2,714 shares to cover exercise price or tax ($11.5K)